- No articles yet.
FDA Panel Backs Moderna mRNA Flu Shot
The FDA's independent vaccine advisors voted 9-0 that the benefits of Moderna's mFlusiva mRNA influenza vaccine outweigh its risks for adults 50 and older.
The unanimous endorsement moves the novel shot a step closer to becoming the first mRNA flu vaccine approved for public use.
The recommendation signals growing confidence in the mRNA platform that was proven during the COVID-19 pandemic.
Moderna hopes the vaccine will improve on traditionally modest flu shot efficacy and eventually be adapted rapidly to emerging strains.
Food and Drug Administration
Myanmar government agency
Myanmar government agency
RNA vaccine
Vaccine that transfects synthetic RNA, reprogramming cells to make foreign protein that stimulates an adaptive immune response
Vaccine that transfects synthetic RNA, reprogramming cells to make foreign protein that stimulates an adaptive immune response
United States
Country located primarily in North America
Country located primarily in North America